LambdaVision is a biotechnology company focused on developing a protein-based artificial retina to restore vision for patients with retinal degenerative diseases. They are pioneering the use of microgravity on the International Space Station (ISS) to improve the manufacturing process of these retinas. LambdaVision partners with organizations like NASA and Space Tango to conduct research and development in low Earth orbit, aiming for commercial-scale production of artificial retinas. Their work involves space-based manufacturing, microgravity research, and biomedical applications.
All verified mentions of this organization in source documents.
LambdaVision used its International Space Station campaign to refine automation routines, fault detection, and quality control protocols before pursuing regulatory clearance.
LambdaVision developed a compact, automated production system with ISS National Lab implementation partner Space Tango.
LambdaVision has not disclosed clinical trial timelines or regulatory filing dates.
LambdaVision’s next International Space Station investigation will focus on increasing production volume and optimizing the manufacturing process.
The ISS National Laboratory sponsored research on LambdaVision’s artificial retina manufacturing campaign.
LambdaVision has reserved capacity on Starlab, the commercial space station under development by Voyager Space and Airbus, for continued in-orbit manufacturing after the International Space Station is retired.
LambdaVision has reserved capacity on Starlab, the commercial space station under development by Voyager Space and Airbus.
LambdaVision’s next ISS investigation is scheduled to launch later this year.
LambdaVision’s ISS campaign helped the company refine automation routines, fault detection, and quality control protocols.
LambdaVision developed a compact automated production system with ISS National Lab implementation partner Space Tango.
LambdaVision’s artificial retina is constructed from hundreds of layers of a light-activated protein.
LambdaVision’s device is designed to replace the function of damaged photoreceptor cells using the protein bacteriorhodopsin.
LambdaVision’s production system is housed inside Space Tango’s CubeLab hardware on the International Space Station.
LambdaVision has developed an automated production system to manufacture a protein-based artificial retina at commercial scale.
LambdaVision’s next International Space Station investigation is scheduled to launch later this year.
LambdaVision’s next ISS investigation will focus on increasing production volume and further optimizing the manufacturing process.
LambdaVision used the International Space Station campaign to refine automation routines, fault detection, and quality control protocols before pursuing regulatory clearance.
LambdaVision’s device is designed to replace the function of damaged photoreceptor cells using bacteriorhodopsin.
LambdaVision and ISS National Lab implementation partner Space Tango developed a compact automated production system housed inside Space Tango’s CubeLab hardware on the International Space Station.
LambdaVision’s artificial retina is built from hundreds of layers of a light-activated protein.